Last 7 days
3.6%
Last 30 days
-6.1%
Last 90 days
-4.6%
Trailing 12 Months
-15.7%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HCA | 73.1B | 60.2B | 6.57% | 2.08% | 12.96 | 1.21 | 2.52% | -18.88% |
LH | 20.6B | 14.9B | -6.12% | -15.74% | 16.07 | 1.38 | -7.72% | -46.20% |
DGX | 16.4B | 9.9B | 0.67% | 1.77% | 17.35 | 1.66 | -8.39% | -52.58% |
MID-CAP | ||||||||
CHE | 8.0B | 2.1B | 1.10% | 3.71% | 32.07 | 3.75 | -0.20% | -7.05% |
DVA | 7.3B | 11.6B | -3.50% | -30.75% | 13.09 | 0.63 | -0.08% | -42.73% |
ACHC | 6.5B | 2.6B | -1.74% | 8.55% | 23.78 | 2.49 | 12.79% | 43.28% |
THC | 6.2B | 19.2B | -1.59% | -33.79% | 6.21 | 0.32 | -1.60% | -32.18% |
EHC | 5.4B | 4.3B | -6.00% | -5.25% | 19.8 | 1.23 | 8.31% | -34.26% |
PGNY | 2.9B | 700.1M | -16.69% | -38.53% | 96.17 | 4.17 | 47.91% | -53.84% |
GH | 2.4B | 449.5M | -25.80% | -65.79% | -3.67 | 5.35 | 20.31% | -70.12% |
SMALL-CAP | ||||||||
RDNT | 1.3B | 1.4B | 3.79% | 9.33% | 123.09 | 0.92 | 8.74% | -56.93% |
HNGR | 732.6M | 1.2B | 0.48% | -14.75% | 19.64 | 0.62 | 11.71% | 25.50% |
XGN | 39.5M | 45.4M | -5.10% | -69.75% | -0.98 | 0.87 | -5.93% | -72.41% |
AMS | 17.3M | 19.4M | -20.38% | 24.15% | 11.77 | 0.89 | 10.55% | 123.93% |
OTRK | 14.0M | 22.3M | -16.26% | -76.89% | -0.22 | 0.63 | -78.33% | -207.64% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -2.5% | 14,877 | 15,259 | 15,715 | 15,859 | 16,121 |
Cost Of Revenue | 0.2% | 10,492 | 10,468 | 10,599 | 10,601 | 10,497 |
Gross Profit | -8.5% | 4,385 | 4,790 | 5,116 | 5,258 | 5,624 |
S&GA Expenses | -0.4% | 1,997 | 2,004 | 2,014 | 1,986 | 1,952 |
Interest Expenses | 3.6% | 180 | 174 | 170 | 206 | 212 |
Net Income | -27.2% | 1,279 | 1,756 | 1,991 | 2,099 | 2,377 |
Net Income Margin | -25.3% | 0.09* | 0.12* | 0.13* | 0.13* | - |
Free Cahsflow | -0.8% | 1,474 | 1,486 | 1,865 | 1,704 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 1.7% | 20,155 | 19,826 | 20,403 | 20,728 | 20,385 |
Current Assets | 5.8% | 4,625 | 4,372 | 5,031 | 5,230 | 5,331 |
Cash Equivalents | 4.9% | 430 | 410 | 1,069 | 1,234 | 1,473 |
Inventory | 0.6% | 471 | 468 | 436 | 441 | 401 |
Net PPE | 2.5% | 2,956 | 2,885 | 2,870 | 2,808 | 2,815 |
Goodwill | -1.2% | 8,121 | 8,218 | 8,114 | 8,166 | 7,959 |
Liabilities | 3.3% | 10,040 | 9,715 | 9,982 | 9,987 | 10,091 |
Current Liabilities | 22.1% | 3,079 | 2,522 | 2,643 | 2,642 | 2,783 |
LT Debt, Non Current | -5.5% | 5,039 | 5,334 | 5,360 | 5,383 | 5,417 |
Shareholder's Equity | 0.0% | 10,097 | 10,092 | 10,401 | 10,721 | 10,273 |
Retained Earnings | -2.4% | 10,582 | 10,845 | 10,898 | 10,948 | 10,457 |
Additional Paid-In Capital | NaN% | - | - | 29.00 | - | - |
Shares Outstanding | -1.5% | 90.00 | 91.00 | 96.00 | 93.00 | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -2.2% | 1,956 | 2,000 | 2,393 | 2,308 | 3,110 |
Share Based Compensation | -7.6% | 144 | 156 | 179 | 163 | 154 |
Cashflow From Investing | -1.2% | -1,652 | -1,633 | -1,477 | -1,325 | -884 |
Cashflow From Financing | 32.5% | -1,322 | -1,958 | -1,787 | -1,633 | -2,065 |
Dividend Payments | Infinity% | 260 | 0.00 | - | - | - |
Buy Backs | -31.2% | 1,100 | 1,600 | 933 | 800 | - |
58.5%
37.7%
19.2%
Y-axis is the maximum loss one would have experienced if Laboratory Corporation of America Holdin was unfortunately bought at previous high price.
9.6%
9.9%
7.0%
19.8%
FIve years rolling returns for Laboratory Corporation of America Holdin.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-27 | Neo Ivy Capital Management | added | 5,331 | 1,183,000 | 1,202,000 | 0.81% |
2023-03-23 | ETF MANAGERS GROUP, LLC | reduced | -37.02 | -368,706 | 968,294 | 0.04% |
2023-03-23 | MetLife Investment Management, LLC | reduced | -3.57 | 534,325 | 5,448,540 | 0.04% |
2023-03-17 | American Portfolios Advisors | reduced | -15.05 | -18,036 | 52,059 | -% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -11.29 | 14,458 | 819,458 | 0.02% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -4.5 | 1,713,530 | 19,193,500 | 0.02% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | unchanged | - | 108,361 | 829,361 | 0.13% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -3.29 | 357,000 | 3,547,000 | 0.02% |
2023-03-03 | TIAA, FSB | reduced | -10.35 | 20,730 | 701,730 | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 93,957 | 93,957 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 11.79% | 10,450,115 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 13.0% | 11,474,507 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 13.0% | 11,474,507 | SC 13G/A | |
Mar 09, 2022 | blackrock inc. | 10.4% | 9,706,541 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 11.24% | 10,753,065 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 8.6% | 8,274,411 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 10.68% | 10,405,602 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 8.0% | 7,832,565 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 11.21% | 10,891,852 | SC 13G/A | |
Feb 05, 2020 | blackrock inc. | 9.1% | 8,855,703 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 217.46 -5.21% | 294.34 28.30% | 382.65 66.79% | 516.07 124.95% | 648.75 182.78% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 30, 2023 | ARS | ARS | |
Mar 30, 2023 | DEF 14A | DEF 14A | |
Mar 30, 2023 | DEFA14A | DEFA14A | |
Mar 27, 2023 | SC 13D | 13D - Major Acquisition | |
Mar 06, 2023 | 4 | Insider Trading | |
Feb 28, 2023 | 10-K | Annual Report | |
Feb 23, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 8-K | Current Report | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 14, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-02 | Summy Amy B. | sold (taxes) | -89,558 | 239 | -374 | evp, chief marketing officer |
2023-03-02 | Summy Amy B. | acquired | - | - | 1,340 | evp, chief marketing officer |
2023-02-21 | Kirchgraber Paul R | sold | -2,004,680 | 250 | -8,000 | ceo, covance drug development |
2023-02-21 | Kirchgraber Paul R | acquired | 547,530 | 182 | 3,000 | ceo, covance drug development |
2023-02-14 | Schroeder Mark S | sold | -76,517 | 247 | -309 | evp, president-diagnostics lab |
2023-02-13 | van der Vaart Sandra D | sold (taxes) | -19,354 | 248 | -78.00 | evp, chief legal officer |
2023-02-13 | BERBERIAN LANCE | sold (taxes) | -21,091 | 248 | -85.00 | evp, cio & cto |
2023-02-13 | Kirchgraber Paul R | sold (taxes) | -35,234 | 248 | -142 | ceo, covance drug development |
2023-02-13 | Schechter Adam H | sold (taxes) | -290,312 | 248 | -1,170 | president & ceo |
2023-02-13 | Caveney Brian J | sold (taxes) | -30,768 | 248 | -124 | evp, president of diagnostics |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Consolidated Statements of Operations [Abstract] | |||
Revenues | $ 14,876.8 | $ 16,120.9 | $ 13,978.5 |
Cost of Revenue | 10,491.7 | 10,496.6 | 9,025.7 |
Gross profit | 4,385.1 | 5,624.3 | 4,952.8 |
Selling, general and administrative expenses | 1,996.6 | 1,952.1 | 1,729.3 |
Amortization of intangibles and other assets | 259.3 | 369.6 | 275.4 |
Goodwill and Intangible Asset Impairment | 271.5 | 0.0 | 462.1 |
Restructuring and other special charges | 83.8 | 43.1 | 40.6 |
Operating income | 1,773.9 | 3,259.5 | 2,445.4 |
Interest expense | (180.3) | (212.1) | (207.4) |
Equity method income, net | 5.4 | 26.5 | 2.9 |
Investment income | 8.9 | 10.2 | 10.3 |
Other, net | (25.3) | 42.5 | (32.1) |
Earnings before income taxes | 1,582.6 | 3,126.6 | 2,219.1 |
Provision for income taxes | 302.0 | 747.1 | 662.1 |
Net earnings | 1,280.6 | 2,379.5 | 1,557.0 |
Less: Net earnings attributable to the noncontrolling interest | (1.5) | (2.2) | (0.9) |
Net earnings attributable to Laboratory Corporation of America Holdings | $ 1,279.1 | $ 2,377.3 | $ 1,556.1 |
CONSOLIDATED BALANCE SHEETS - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | |
Statement of Financial Position [Abstract] | ||
Deferred Revenue, Revenue Recognized | $ 330,500,000 | $ 319,400,000 |
Current assets: | ||
Cash and Cash Equivalents, at Carrying Value | 430,000,000.0 | 1,472,700,000 |
Accounts receivable, net | 2,222,000,000 | 2,261,500,000 |
Unbilled Contracts Receivable | 795,400,000 | 716,800,000 |
Supplies inventory | 470,600,000 | 401,400,000 |
Prepaid expenses and other | 707,000,000.0 | 478,100,000 |
Total current assets | 4,625,000,000 | 5,330,500,000 |
Property, plant and equipment, net | 2,956,200,000 | 2,815,400,000 |
Goodwill, net | 8,121,000,000 | 7,958,900,000 |
Intangible assets, net | 3,946,900,000 | 3,735,500,000 |
Joint venture partnerships and equity method investments | 65,700,000 | 60,900,000 |
Deferred Income Tax Assets, Net | 7,600,000 | 21,600,000 |
Other assets, net | 432,700,000 | 462,600,000 |
Total assets | 20,155,100,000 | 20,385,400,000 |
Current liabilities: | ||
Finance Lease, Liability, Current | 6,000,000.0 | 10,500,000 |
Accounts payable | 934,800,000 | 621,300,000 |
Accrued expenses and other | 1,068,800,000 | 1,404,100,000 |
Deferred Revenue, Current | 582,100,000 | 558,500,000 |
Operating Lease, Liability, Current | 185,500,000 | 187,000,000.0 |
Short-term borrowings and current portion of long-term debt | 301,300,000 | 1,500,000 |
Total current liabilities | 3,078,500,000 | 2,782,900,000 |
Long-term debt, less current portion | 5,038,800,000 | 5,416,500,000 |
Total maturities, due beyond one year | 679,700,000 | 642,500,000 |
Total maturities, due beyond one year | 83,600,000 | 84,600,000 |
Deferred income taxes and other tax liabilities | 736,200,000 | 762,900,000 |
Other liabilities | 422,800,000 | 402,000,000.0 |
Total liabilities | 10,039,600,000 | 10,091,400,000 |
Commitments and contingent liabilities | ||
Noncontrolling interest | 18,900,000 | 20,600,000 |
Shareholders’ equity | ||
Common stock, 88.2 and 93.1 shares outstanding at December 31, 2022 and 2021, respectively | 8,100,000 | 8,500,000 |
Retained earnings | 10,581,700,000 | 10,456,800,000 |
Accumulated other comprehensive loss | (493,200,000) | (191,900,000) |
Total shareholders’ equity | 10,096,600,000 | 10,273,400,000 |
Total liabilities and shareholders’ equity | $ 20,155,100,000 | $ 20,385,400,000 |